BioStem Technologies: Matuszewski reports 17.4% stake
Certain restricted stock units and options covering 497,411 and 440,529 shares, respectively, were not scheduled to vest on or before November 29, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
BioStem Technologies, Inc. (BSEM) reported that Jason Matuszewski beneficially owned 3,665,899 shares of Common Stock, or 17.4% of the class, as of September 30, 2026. The total includes 1,303,551 shares held directly, 2,250,000 shares issuable under fully vested options with a $2.00 exercise price, and additional shares issuable under other options and convertible preferred stock.
The percentage calculation uses 18,672,125 shares outstanding as of October 1, 2026, plus 2,362,348 shares issuable to him within 60 days of September 30, 2026. The reported ownership excludes restricted stock units covering 497,411 shares and options for 440,529 shares, neither scheduled to vest on or before November 29, 2026.
Key Figures
Key Terms
beneficially owned financial
Sole Voting Power financial
Sole Dispositive Power financial
restricted stock units financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What securities are included in Jason Matuszewski's BSEM ownership?
AI-generated analysis. How Rhea-AI works. Not financial advice.